Personalized radioiodine therapy for thyroid cancer patients with known disease.

Radioactive iodine (RAI) I is a targeted therapy for patients with RAI-avid follicular cell-derived thyroid cancer. However, the responsiveness to I therapy varies among thyroid cancer patients mainly owing to differential RAI uptake and RAI radiosensitivity among patients' lesions. A personalized approach to maximize I therapeutic efficacy is proposed based on recent scientific advances and future opportunities.